Genespire develops immune-shielded lentiviral vectors to deliver gene therapies for children with genetic diseases. The company aims to provide these patients with effective treatment options that can significantly improve their quality of life.
Funding
$69.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
XVFounders
Product
Problem
Children with genetic diseases often lack effective treatment options, significantly impacting their quality of life and overall health outcomes. Traditional gene therapies can be limited by immune responses, reducing their efficacy and potentially causing adverse reactions.
Solution
Genespire is developing immune-shielded lentiviral vectors designed to deliver gene therapies to children with genetic diseases. These vectors aim to overcome the limitations of traditional gene therapies by minimizing immune responses, thereby enhancing the effectiveness and safety of the treatment. The company's mission is to enable children affected by genetic diseases to benefit from the life-changing potential of gene therapy.
Target Audience
The primary target audience includes children affected by genetic diseases and their families, as well as healthcare providers specializing in pediatric genetics and gene therapy.
Features
- Immune-shielded lentiviral vectors for gene therapy delivery
- Targeted treatment for children with genetic diseases
- Enhanced efficacy and safety compared to traditional gene therapies